Boditech Med Showcases Innovative IVD Solutions at CACLP 2025 in China
• Cardiovascular and acute chest pain diagnostic panel, featuring ST2 & NT-proBNP, draws significant attention
• Strengthened partnerships with Chinese firms set the stage for broader market entry
• High interest in Korean diagnostic technology, with expectations for increased collaboration
Boditech Med, a leading provider of point-of-care diagnostic solutions, announced on March 24 that it participated in CACLP 2025, held from March 22 to 24 at the Grand Convention Center in Hangzhou, China.
CACLP, launched in 1991, is the world’s largest in vitro diagnostics (IVD) exhibition. Now in its 22nd year, the event brings together more than 1,300 companies from over 40 countries and attracts over 40,000 industry professionals annually. It serves as a global platform for sharing cutting-edge technologies and building strategic partnerships.
At CACLP 2025, Boditech Med unveiled a range of innovative IVD solutions, drawing strong interest from attendees. In particular, the company’s next-generation cardiovascular biomarkers ST2 and NT-proBNP, along with its acute chest pain and dyspnea diagnostic panel, attracted attention from medical professionals and exhibition visitors. Many attendees visited the Boditech Med booth for product demonstrations and discussions on clinical applications. The event also provided opportunities to engage with global companies and healthcare institutions, leading to the creation of several new business partnerships.
Boditech Med’s dual-detection system for ST2 & NT-proBNP is designed to improve prognosis evaluation and treatment monitoring for heart failure patients. The system delivers results in under 12 minutes and enables whole blood testing without centrifugation, simplifying the diagnostic process and enhancing efficiency.
The company also showcased its acute chest pain diagnostic panel (cTnI/NT-proBNP/D-Dimer), which enables rapid differential diagnosis of emergency cardiovascular conditions such as myocardial infarction, heart failure, and thromboembolic pulmonary embolism. The panel simultaneously measures three critical markers in a single test, providing fast and accurate results.
In addition, Boditech Med introduced a quantitative calprotectin test for differentiating inflammatory bowel disease (IBD) and infectious diarrhea. With high sensitivity and specificity, the test helps reducing the need for colonoscopy, offering an economical diagnostic alternative. A new thrombosis panel compatible with Boditech Med’s compact chemiluminescence analyzer was also presented.
Eui-yeol Choi, CEO of Boditech Med, stated, “This exhibition reaffirmed Boditech Med’s technological competitiveness in the global IVD market. Through meetings with Chinese partners, we explored opportunities to expand into various diagnostic sectors, including CBC and clinical chemistry.” He added, “As the president of the Korea In Vitro Diagnostics Association, I led the Korean delegation to CACLP for the first time. We received strong interest in Korean technology and collaborative potential, and I believe this event will further promote exchange and cooperation between Korean and Chinese IVD companies.”